MCID: INF037
MIFTS: 54

Inflammatory Bowel Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Inflammatory Bowel Disease

MalaCards integrated aliases for Inflammatory Bowel Disease:

Name: Inflammatory Bowel Disease 12 37 29 6 3 15
Inflammatory Bowel Diseases 55 44 73
Bowel Disease, Inflammatory 40

Classifications:



External Ids:

Disease Ontology 12 DOID:0050589
MeSH 44 D015212
NCIt 50 C3138
SNOMED-CT 68 24526004
KEGG 37 H01227
UMLS 73 C0021390

Summaries for Inflammatory Bowel Disease

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

MalaCards based summary : Inflammatory Bowel Disease, also known as inflammatory bowel diseases, is related to inflammatory bowel disease 5 and inflammatory bowel disease 2. An important gene associated with Inflammatory Bowel Disease is CBR3-AS1 (CBR3 Antisense RNA 1), and among its related pathways/superpathways are Antigen processing and presentation and Cytokine-cytokine receptor interaction. The drugs Iron and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include colon, bone and testes.

Disease Ontology : 12 An intestinal disease characterized by inflammation located in all parts of digestive tract.

Wikipedia : 76 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.... more...

Related Diseases for Inflammatory Bowel Disease

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 29 Inflammatory Bowel Disease 28
Inflammatory Bowel Disease 25

Diseases related to Inflammatory Bowel Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 508)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 5 34.6 IBD5 IL23R NOD2
2 inflammatory bowel disease 2 34.5 IBD2 NOD2
3 inflammatory bowel disease 9 34.5 IBD9 NOD2
4 inflammatory bowel disease 4 34.4 IBD4 NOD2
5 inflammatory bowel disease 8 34.4 IBD8 NOD2
6 inflammatory bowel disease 3 34.4 IBD3 NOD2
7 inflammatory bowel disease 7 34.4 IBD7 NOD2
8 inflammatory bowel disease 6 34.1 IBD6 NOD2
9 inflammatory bowel disease 1 12.7
10 inflammatory bowel disease 25, autosomal recessive 12.7
11 inflammatory bowel disease 20 12.6
12 inflammatory bowel disease 19 12.6
13 inflammatory bowel disease 10 12.6
14 inflammatory bowel disease 28, autosomal recessive 12.6
15 inflammatory bowel disease 17 12.6
16 inflammatory bowel disease 13 12.6
17 inflammatory bowel disease 14 12.6
18 inflammatory bowel disease 16 12.5
19 inflammatory bowel disease 18 12.5
20 inflammatory bowel disease 11 12.5
21 inflammatory bowel disease 12 12.5
22 inflammatory bowel disease 15 12.5
23 inflammatory bowel disease 21 12.5
24 inflammatory bowel disease 22 12.5
25 inflammatory bowel disease 23 12.5
26 inflammatory bowel disease 24 12.5
27 inflammatory bowel disease 26 12.5
28 inflammatory bowel disease 27 12.5
29 inflammatory bowel disease 28 12.5
30 inflammatory bowel disease 25 12.5
31 inflammatory bowel disease 29 12.5
32 ulcerative colitis 12.1
33 gastrointestinal defects and immunodeficiency syndrome 11.8
34 crohn's disease 11.6
35 irritable bowel syndrome 11.6
36 cholangitis, primary sclerosing 11.6
37 colitis 11.5
38 spondyloarthropathy 1 11.5
39 ileitis 11.5
40 collagenous colitis 11.5
41 glycogen storage disease ib 11.5
42 ileocolitis 11.5
43 crohn's colitis 11.4
44 proctitis 11.4
45 chronic recurrent multifocal osteomyelitis 11.3
46 lymphoproliferative syndrome, x-linked, 2 11.3
47 pain - chronic 11.3
48 immunodeficiency, common variable, 11 11.2
49 neonatal inflammatory skin and bowel disease 11.2
50 lymphoproliferative syndrome, x-linked, 1 11.2

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease:



Diseases related to Inflammatory Bowel Disease

Symptoms & Phenotypes for Inflammatory Bowel Disease

Drugs & Therapeutics for Inflammatory Bowel Disease

Drugs for Inflammatory Bowel Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 557)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 58-05-9 6006 143
3
Tocopherol Approved, Investigational Phase 4,Phase 2,Not Applicable 1406-66-2 14986
4
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
5
Copper Approved, Investigational Phase 4 7440-50-8 27099
6
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 170277-31-3
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
9
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
11
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
12
Clarithromycin Approved Phase 4,Phase 3,Not Applicable 81103-11-9 84029
13
Clofazimine Approved, Investigational Phase 4,Phase 3 2030-63-9 2794
14
Rifabutin Approved, Investigational Phase 4,Phase 3 72559-06-9 6323490
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
16
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
17
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
18
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
19
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
20 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
22
Rosiglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 122320-73-4 77999
23 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 943609-66-3
24
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
25
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
26
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
27
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
28
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
30
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
31
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
32
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
33
Bupropion Approved Phase 4,Phase 2,Phase 3 34841-39-9, 34911-55-2 444
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
35
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
36
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
37
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
38
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
39
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
40
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
41
Ibuprofen Approved Phase 4 15687-27-1 3672
42
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
43
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
44
Azithromycin Approved Phase 4 83905-01-5 55185 447043
45
Phytonadione Approved, Investigational Phase 4,Phase 1 84-80-0 4812 5284607
46
Budesonide Approved Phase 4,Phase 3,Phase 2 51333-22-3 63006 5281004
47
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 189261-10-7
48
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
49
Thioguanine Approved Phase 4,Phase 1 154-42-7 2723601
50
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474

Interventional clinical trials:

(show top 50) (show all 2116)
# Name Status NCT ID Phase Drugs
1 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
2 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
3 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
4 Vitamin D Substitution During Winter Time Unknown status NCT02958501 Phase 4 Colecalciferol
5 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
6 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
7 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
8 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
9 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Unknown status NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
10 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
11 Does Clinical Response Correlate With Serum Certolizumab Levels? Unknown status NCT02597829 Phase 4 Certolizumab Pegol
12 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
13 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
14 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
15 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
16 Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
17 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission Unknown status NCT01817426 Phase 4 Infliximab
18 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
19 Optimizing Cimzia in Crohn's Patients Unknown status NCT01024647 Phase 4
20 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
21 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
22 VSL#3 Treatment in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
23 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
24 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
25 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
26 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
27 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
28 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
29 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
30 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
31 Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
32 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease Completed NCT02162862 Phase 4 bupropion-SR
33 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
34 Low Volume Colon Preparation for IBD Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
35 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
36 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
37 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
38 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
39 Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Completed NCT02946203 Phase 4
40 Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
41 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed NCT00746395 Phase 4 Lubiprostone;Placebo
42 Gene Regulation by Thiazolidinediones Completed NCT00567593 Phase 4 Rosiglitazone
43 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
44 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
45 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Completed NCT02010762 Phase 4 Vitamin D;Placebo
46 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4 mesalamine
47 Pneumococcal Vaccination of Crohn Patients Completed NCT01947010 Phase 4
48 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
49 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
50 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo

Search NIH Clinical Center for Inflammatory Bowel Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: inflammatory bowel diseases

Genetic Tests for Inflammatory Bowel Disease

Genetic tests related to Inflammatory Bowel Disease:

# Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 29

Anatomical Context for Inflammatory Bowel Disease

MalaCards organs/tissues related to Inflammatory Bowel Disease:

41
Colon, Bone, Testes, T Cells, Liver, Small Intestine, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Inflammatory Bowel Disease:

19
All Parts Of Digestive Tract

Publications for Inflammatory Bowel Disease

Articles related to Inflammatory Bowel Disease:

(show top 50) (show all 5031)
# Title Authors Year
1
Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage. ( 30485467 )
2019
2
Excluding irritable bowel syndrome in the inflammatory bowel disease patient: how far to go? ( 30407259 )
2019
3
Effect of recombinant Trichinella spiralis cysteine proteinase inhibitor on TNBS-induced experimental inflammatory bowel disease in mice. ( 30419451 )
2019
4
Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids. ( 30430615 )
2019
5
Association between inflammatory bowel disease and uveal melanoma: case report of two young adults and a literature review. ( 30455614 )
2019
6
Early-Onset Inflammatory Bowel Disease. ( 30466773 )
2019
7
The role of obesity in inflammatory bowel disease. ( 30352258 )
2019
8
Investing in workability of patients with inflammatory bowel disease: results of a pilot project Activ84worK (Activate for work). ( 30192245 )
2019
9
Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges. ( 29430322 )
2018
10
Decreased risk for microscopic colitis and inflammatory bowel disease among patients with reflux disease. ( 29603881 )
2018
11
Inflammatory bowel disease and acute anterior uveitis, but not psoriasis are associated with disease duration in Axial SpA: results from the (Be)Giant and ASPECT cohort. ( 29740978 )
2018
12
Cytomegalovirus infection and steroid-refractory inflammatory bowel disease: possible relationship from an updated meta-analysis. ( 29392650 )
2018
13
The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies. ( 29956079 )
2018
14
The pre-treatment characteristics and evaluation of the effects of recombinant human growth hormone therapy in children with growth hormone deficiency and celiac disease or inflammatory bowel disease. ( 29736148 )
2018
15
The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014. ( 29431201 )
2018
16
Risk factors for low bone mineral density in pediatric inflammatory bowel disease: the positive role of physical activity. ( 29438136 )
2018
17
The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. ( 29435321 )
2018
18
How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. ( 29957083 )
2018
19
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? ( 29432749 )
2018
20
Prevalence of inflammatory bowel disease in alcoholic, non-alcoholic and autoimmune pancreatitis. ( 29734447 )
2018
21
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. ( 29430672 )
2018
22
Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. ( 29378308 )
2018
23
De-escalation of Therapy in Inflammatory Bowel Disease. ( 29961926 )
2018
24
Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. ( 29862092 )
2018
25
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. ( 29377235 )
2018
26
Reply: Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. ( 29314243 )
2018
27
Increased risk for inflammatory bowel disease in congenital hypothyroidism supports the existence of a shared susceptibility factor. ( 29977049 )
2018
28
Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease. ( 29457211 )
2018
29
A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease. ( 29968143 )
2018
30
Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis. ( 29440920 )
2018
31
Association between Inflammatory Bowel Disease and Cholelithiasis: A Nationwide Population-Based Cohort Study. ( 29538289 )
2018
32
Vitamin D: a brief overview of its importance and role in inflammatory bowel disease. ( 29971262 )
2018
33
Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. ( 29424814 )
2018
34
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )
2018
35
Low childhood high density lipoprotein cholesterol levels and subsequent risk for chronic inflammatory bowel disease. ( 29426615 )
2018
36
High level of IgG4 as a biomarker for a new subset of inflammatory bowel disease. ( 29968792 )
2018
37
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. ( 29808485 )
2018
38
Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. ( 29430323 )
2018
39
How ameliorate the adherence in patients with inflammatory bowel disease? ( 29969048 )
2018
40
TTC7A mutation must be considered in patients with repeated intestinal atresia associated with early inflammatory bowel disease: Two new case reports and a literature review. ( 29921470 )
2018
41
Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. ( 29617820 )
2018
42
Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. ( 29437914 )
2018
43
Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. ( 29972674 )
2018
44
Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn's & Colitis Foundation: Charting the Future of Pediatric IBD. ( 29931102 )
2018
45
Toll-like Receptors and Inflammatory Bowel Disease. ( 29441063 )
2018
46
Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. ( 29440933 )
2018
47
Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease. ( 29357084 )
2018
48
Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease. ( 29971936 )
2018
49
Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice. ( 29955835 )
2018
50
Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease. ( 29484893 )
2018

Variations for Inflammatory Bowel Disease

ClinVar genetic disease variations for Inflammatory Bowel Disease:

6 (show top 50) (show all 170)
# Gene Variation Type Significance SNP ID Assembly Location
1 IL10RB NM_000628.4(IL10RB): c.139A> G (p.Lys47Glu) single nucleotide variant Benign rs2834167 GRCh37 Chromosome 21, 34640788: 34640788
2 IL10RB NM_000628.4(IL10RB): c.139A> G (p.Lys47Glu) single nucleotide variant Benign rs2834167 GRCh38 Chromosome 21, 33268483: 33268483
3 IL10RA NM_001558.3(IL10RA): c.475A> G (p.Ser159Gly) single nucleotide variant Benign/Likely benign rs3135932 GRCh37 Chromosome 11, 117864063: 117864063
4 IL10RA NM_001558.3(IL10RA): c.475A> G (p.Ser159Gly) single nucleotide variant Benign/Likely benign rs3135932 GRCh38 Chromosome 11, 117993348: 117993348
5 IL10RA NM_001558.3(IL10RA): c.781C> T (p.Arg261Trp) single nucleotide variant Uncertain significance rs201396764 GRCh38 Chromosome 11, 117995681: 117995681
6 IL10RA NM_001558.3(IL10RA): c.781C> T (p.Arg261Trp) single nucleotide variant Uncertain significance rs201396764 GRCh37 Chromosome 11, 117866396: 117866396
7 IL10RA NM_001558.3(IL10RA): c.931T> C (p.Leu311=) single nucleotide variant Conflicting interpretations of pathogenicity rs148808529 GRCh37 Chromosome 11, 117869550: 117869550
8 IL10RA NM_001558.3(IL10RA): c.931T> C (p.Leu311=) single nucleotide variant Conflicting interpretations of pathogenicity rs148808529 GRCh38 Chromosome 11, 117998835: 117998835
9 IL10RA NM_001558.3(IL10RA): c.67+15C> T single nucleotide variant Uncertain significance rs886047708 GRCh37 Chromosome 11, 117857264: 117857264
10 IL10RA NM_001558.3(IL10RA): c.67+15C> T single nucleotide variant Uncertain significance rs886047708 GRCh38 Chromosome 11, 117986549: 117986549
11 IL10RA NM_001558.3(IL10RA): c.144C> T (p.Ile48=) single nucleotide variant Conflicting interpretations of pathogenicity rs140466541 GRCh37 Chromosome 11, 117859173: 117859173
12 IL10RA NM_001558.3(IL10RA): c.144C> T (p.Ile48=) single nucleotide variant Conflicting interpretations of pathogenicity rs140466541 GRCh38 Chromosome 11, 117988458: 117988458
13 IL10RA NM_001558.3(IL10RA): c.1281C> T (p.Pro427=) single nucleotide variant Uncertain significance rs767275130 GRCh37 Chromosome 11, 117869900: 117869900
14 IL10RA NM_001558.3(IL10RA): c.1281C> T (p.Pro427=) single nucleotide variant Uncertain significance rs767275130 GRCh38 Chromosome 11, 117999185: 117999185
15 IL10RA NM_001558.3(IL10RA): c.1452G> A (p.Glu484=) single nucleotide variant Uncertain significance rs139576148 GRCh37 Chromosome 11, 117870071: 117870071
16 IL10RA NM_001558.3(IL10RA): c.1452G> A (p.Glu484=) single nucleotide variant Uncertain significance rs139576148 GRCh38 Chromosome 11, 117999356: 117999356
17 IL10RA NM_001558.3(IL10RA): c.*354T> C single nucleotide variant Likely benign rs4252292 GRCh37 Chromosome 11, 117870710: 117870710
18 IL10RA NM_001558.3(IL10RA): c.*354T> C single nucleotide variant Likely benign rs4252292 GRCh38 Chromosome 11, 117999995: 117999995
19 IL10RA NM_001558.3(IL10RA): c.*639C> T single nucleotide variant Uncertain significance rs562410825 GRCh37 Chromosome 11, 117870995: 117870995
20 IL10RA NM_001558.3(IL10RA): c.*639C> T single nucleotide variant Uncertain significance rs562410825 GRCh38 Chromosome 11, 118000280: 118000280
21 IL10RA NM_001558.3(IL10RA): c.*863C> T single nucleotide variant Uncertain significance rs779722798 GRCh38 Chromosome 11, 118000504: 118000504
22 IL10RA NM_001558.3(IL10RA): c.*863C> T single nucleotide variant Uncertain significance rs779722798 GRCh37 Chromosome 11, 117871219: 117871219
23 IL10RA NM_001558.3(IL10RA): c.*866C> A single nucleotide variant Uncertain significance rs145605428 GRCh38 Chromosome 11, 118000507: 118000507
24 IL10RA NM_001558.3(IL10RA): c.*866C> A single nucleotide variant Uncertain significance rs145605428 GRCh37 Chromosome 11, 117871222: 117871222
25 IL10RA NM_001558.3(IL10RA): c.*1058A> G single nucleotide variant Uncertain significance rs886047712 GRCh38 Chromosome 11, 118000699: 118000699
26 IL10RA NM_001558.3(IL10RA): c.*1058A> G single nucleotide variant Uncertain significance rs886047712 GRCh37 Chromosome 11, 117871414: 117871414
27 IL10RA NM_001558.3(IL10RA): c.*1348G> C single nucleotide variant Likely benign rs4252293 GRCh38 Chromosome 11, 118000989: 118000989
28 IL10RA NM_001558.3(IL10RA): c.*1348G> C single nucleotide variant Likely benign rs4252293 GRCh37 Chromosome 11, 117871704: 117871704
29 IL10RA NM_001558.3(IL10RA): c.*1375C> A single nucleotide variant Uncertain significance rs141609122 GRCh37 Chromosome 11, 117871731: 117871731
30 IL10RA NM_001558.3(IL10RA): c.*1375C> A single nucleotide variant Uncertain significance rs141609122 GRCh38 Chromosome 11, 118001016: 118001016
31 IL10RA NM_001558.3(IL10RA): c.96G> A (p.Val32=) single nucleotide variant Uncertain significance rs377525753 GRCh37 Chromosome 11, 117859125: 117859125
32 IL10RA NM_001558.3(IL10RA): c.96G> A (p.Val32=) single nucleotide variant Uncertain significance rs377525753 GRCh38 Chromosome 11, 117988410: 117988410
33 IL10RA NM_001558.3(IL10RA): c.181C> G (p.Leu61Val) single nucleotide variant Benign/Likely benign rs4252250 GRCh37 Chromosome 11, 117859210: 117859210
34 IL10RA NM_001558.3(IL10RA): c.181C> G (p.Leu61Val) single nucleotide variant Benign/Likely benign rs4252250 GRCh38 Chromosome 11, 117988495: 117988495
35 IL10RA NM_001558.3(IL10RA): c.337G> A (p.Val113Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs4252303 GRCh37 Chromosome 11, 117860305: 117860305
36 IL10RA NM_001558.3(IL10RA): c.337G> A (p.Val113Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs4252303 GRCh38 Chromosome 11, 117989590: 117989590
37 IL10RA NM_001558.3(IL10RA): c.459A> G (p.Ala153=) single nucleotide variant Benign rs2256111 GRCh37 Chromosome 11, 117864047: 117864047
38 IL10RA NM_001558.3(IL10RA): c.459A> G (p.Ala153=) single nucleotide variant Benign rs2256111 GRCh38 Chromosome 11, 117993332: 117993332
39 IL10RA NM_001558.3(IL10RA): c.670A> G (p.Ile224Val) single nucleotide variant Benign rs2228055 GRCh37 Chromosome 11, 117864846: 117864846
40 IL10RA NM_001558.3(IL10RA): c.670A> G (p.Ile224Val) single nucleotide variant Benign rs2228055 GRCh38 Chromosome 11, 117994131: 117994131
41 IL10RA NM_001558.3(IL10RA): c.785G> A (p.Arg262His) single nucleotide variant Uncertain significance rs202121581 GRCh37 Chromosome 11, 117866400: 117866400
42 IL10RA NM_001558.3(IL10RA): c.785G> A (p.Arg262His) single nucleotide variant Uncertain significance rs202121581 GRCh38 Chromosome 11, 117995685: 117995685
43 IL10RA NM_001558.3(IL10RA): c.810+10G> A single nucleotide variant Uncertain significance rs12290349 GRCh37 Chromosome 11, 117866435: 117866435
44 IL10RA NM_001558.3(IL10RA): c.810+10G> A single nucleotide variant Uncertain significance rs12290349 GRCh38 Chromosome 11, 117995720: 117995720
45 IL10RA NM_001558.3(IL10RA): c.1051A> G (p.Arg351Gly) single nucleotide variant Benign rs2229113 GRCh37 Chromosome 11, 117869670: 117869670
46 IL10RA NM_001558.3(IL10RA): c.1051A> G (p.Arg351Gly) single nucleotide variant Benign rs2229113 GRCh38 Chromosome 11, 117998955: 117998955
47 IL10RA NM_001558.3(IL10RA): c.1259C> T (p.Ser420Leu) single nucleotide variant Benign/Likely benign rs2229114 GRCh37 Chromosome 11, 117869878: 117869878
48 IL10RA NM_001558.3(IL10RA): c.1259C> T (p.Ser420Leu) single nucleotide variant Benign/Likely benign rs2229114 GRCh38 Chromosome 11, 117999163: 117999163
49 IL10RA NM_001558.3(IL10RA): c.1323G> A (p.Val441=) single nucleotide variant Uncertain significance rs746663189 GRCh37 Chromosome 11, 117869942: 117869942
50 IL10RA NM_001558.3(IL10RA): c.1323G> A (p.Val441=) single nucleotide variant Uncertain significance rs746663189 GRCh38 Chromosome 11, 117999227: 117999227

Expression for Inflammatory Bowel Disease

Search GEO for disease gene expression data for Inflammatory Bowel Disease.

Pathways for Inflammatory Bowel Disease

Pathways related to Inflammatory Bowel Disease according to KEGG:

37
# Name Kegg Source Accession
1 Antigen processing and presentation hsa04612
2 Cytokine-cytokine receptor interaction hsa04060
3 JAK-STAT signaling pathway hsa04630
4 Inflammatory bowel disease (IBD) hsa05321
5 Autophagy - animal hsa04140

GO Terms for Inflammatory Bowel Disease

Biological processes related to Inflammatory Bowel Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of interleukin-17 production GO:0032740 8.62 IL23R NOD2

Sources for Inflammatory Bowel Disease

3 CDC
7